Status:
COMPLETED
Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).
Lead Sponsor:
Pfizer
Conditions:
Smoking Cessation
Eligibility:
All Genders
35+ years
Phase:
PHASE3
Brief Summary
This study is to be conducted in subjects with mild-to-moderate COPD who are cigarette smokers with the intent of demonstrating differences in smoking cessation between varenicline and placebo.
Eligibility Criteria
Inclusion
- Subjects will be current cigarette smokers who have smoked an average of at least 10 cigarettes per day during the past year and during the month prior to the screening visit.
- mild to moderate COPD confirmed by spirometry
- Subjects must have a clinical diagnosis of COPD.
Exclusion
- Subjects who have made a serious attempt to quit smoking in the past 3 months.
- Subjects who have been previously randomized in a study that has included varenicline.
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
504 Patients enrolled
Trial Details
Trial ID
NCT00285012
Start Date
May 1 2006
End Date
April 1 2009
Last Update
April 20 2010
Active Locations (32)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Birmingham, Alabama, United States, 35249-2181
2
Pfizer Investigational Site
Los Angeles, California, United States, 90095-1690
3
Pfizer Investigational Site
Los Angeles, California, United States, 90095-6984
4
Pfizer Investigational Site
Denver, Colorado, United States, 80206